I'm not sure what this means, but I thought maybe it could possibly help- it's from the Genentech website-
"In addition, Genentech plans to open an Expanded Access Program (EAP) in the United States to provide, under certain circumstances, people with HER2-positive mBC access to trastuzumab emtansine while the company seeks regulatory approval."
http://www.gene.com/gene/news/press-...etail&id=14147